The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.1
Olaparib is specifically recommended as a maintenance treatment option for adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy only if they harbor a BRCA1/2
mutation, they received ≥3 courses of platinum-based chemotherapy, and the manufacturer provides the agent according to the commercial arrangement.
Moreover, the PARP inhibitor has also been recommended for use within the Cancers Drugs Fund as a maintenance treatment option in this patient population if they harbor a BRCA1/2
mutation, they previously received 2 courses of platinum-based chemotherapy, and the conditions in the managed access agreement for the PARP inhibitor are followed.
... to read the full story